Rocket Pharmaceuticals (RCKT) counsel sells shares to cover RSU tax withholding

Rhea-AI Filing Summary

Rocket Pharmaceuticals General Counsel Wilson Martin reported an open-market sale of company stock. On February 18, 2026, he sold 1,376 shares of Common Stock at an average price of $3.338 per share in a transaction classified as an open-market sale.

According to the footnotes, the shares were sold to pay tax withholding obligations arising from the vesting of Restricted Stock Units (RSUs). After this sale, Martin beneficially owned 682,000 shares, which include RSUs that convert to common stock on a one-for-one basis.

Insider Trade Summary

Net Seller: 1,376 shares ($4,593)

Net Sell 1 txn

Insider Wilson Martin

Role General Counsel

Sold 1,376 shs ($5K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,376	$3.338	$5K

Holdings After Transaction: Common Stock — 682,000 shares (Direct)

Footnotes (1)

1. Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wilson Martin

(Last) (First) (Middle)

C/O ROCKET PHARMACEUTICALS, INC.

9 CEDARBROOK DRIVE

(Street)

CRANBURY NJ 08512

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ROCKET PHARMACEUTICALS, INC. [ RCKT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	General Counsel

3. Date of Earliest Transaction (Month/Day/Year)
02/18/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	02/18/2026		S(2)		1,376	D	$3.338	682,000(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis.

2. The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs.

	/s/ Martin Louis Wilson	02/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Rocket Pharmaceuticals (RCKT) report for Wilson Martin?

Rocket Pharmaceuticals reported that General Counsel Wilson Martin sold 1,376 shares of common stock. The sale was an open-market transaction used to cover tax withholding from vested RSUs, and did not significantly change his overall ownership position.

How many Rocket Pharmaceuticals (RCKT) shares did the General Counsel sell and at what price?

General Counsel Wilson Martin sold 1,376 shares of Rocket Pharmaceuticals common stock at an average price of $3.338 per share. This was a relatively small sale compared with his remaining reported holdings after the transaction.

Why did Rocket Pharmaceuticals (RCKT) General Counsel sell shares in this Form 4 filing?

The filing states that the 1,376 shares were sold to pay tax withholding obligations related to the vesting of Restricted Stock Units. This indicates the transaction was primarily tax-driven rather than a discretionary reduction of his investment position.

How many Rocket Pharmaceuticals (RCKT) shares does Wilson Martin hold after the reported sale?

After the sale, General Counsel Wilson Martin reported beneficial ownership of 682,000 shares of Rocket Pharmaceuticals common stock. This total includes Restricted Stock Units that convert to common stock on a one-for-one basis upon vesting or settlement.

What type of security and code were reported in this Rocket Pharmaceuticals (RCKT) Form 4?

The Form 4 reports a transaction in Common Stock using transaction code S, which indicates a sale in the open market or a private transaction. The filing classifies it as a non-derivative transaction by the company’s General Counsel.

Do the Rocket Pharmaceuticals (RCKT) Form 4 footnotes mention Restricted Stock Units (RSUs)?

Yes. The footnotes explain that Martin’s holdings include Restricted Stock Units that convert to common stock on a one-for-one basis. They also state that the reported sale was executed to satisfy tax withholding obligations from the RSU vesting.